Feasibility and efficacy of chemoradiotherapy with concurrent split‑dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5‑fluorouracil for locally advanced head and neck cancer

Yokota,Tomoya; Shibata,Masayuki; Hamauchi,Satoshi; Shirasu,Hiromichi; Onozawa,Yusuke; Ogawa,Hirofumi; Onoe,Tsuyoshi; Kawakami,Takeshi; Furuta,Mitsuhiro; Inoue,Hiroto; Fushiki,Kunihiro; Onitsuka,Tetsuro

doi:10.3892/mco.2020.2105

Feasibility and efficacy of chemoradiotherapy with concurrent split‑dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5‑fluorouracil for locally advanced head and neck cancer

Authors:
- Tomoya Yokota
- Masayuki Shibata
- Satoshi Hamauchi
- Hiromichi Shirasu
- Yusuke Onozawa
- Hirofumi Ogawa
- Tsuyoshi Onoe
- Takeshi Kawakami
- Mitsuhiro Furuta
- Hiroto Inoue
- Kunihiro Fushiki
- Tetsuro Onitsuka
View Affiliations

Affiliations: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka 411‑8777, Japan, Division of Medical Oncology, Shizuoka Cancer Center, Shizuoka 411‑8777, Japan, Division of Radiation Oncology, Shizuoka Cancer Center, Shizuoka 411‑8777, Japan, Division of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka 411‑8777, Japan
Published online on: July 31, 2020 https://doi.org/10.3892/mco.2020.2105
Article Number: 35

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoradiotherapy (CRT) with concurrent high‑dose cisplatin (CDDP) is a standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA‑SCCHN). Docetaxel plus CDDP and 5‑fluorouracil (TPF) induction chemotherapy (ICT) prior to CRT is considered for patients at high risk of distant metastases. The purpose of the current study was to evaluate the feasibility and efficacy of CRT with split‑dose CDDP after TPF‑ICT for LA‑SCCHN. A total of 21 LA‑SCCHN patients treated with TPF‑ICT followed by concurrent CRT with split‑dose CDDP between January 2011 and December 2017 were retrospectively analysed. The patients' characteristics were i) median age 66 years (48‑75 years); ii) male/female, 21/0; iii) performance status 0‑1/2, 20/1; iv) larynx/hypopharynx/oropharynx/oral cavity, 4/8/8/1 and v) clinical stage III/IV, 3/18. The numbers of TPF‑ICT cycles 1/2/3 were 2/3/16. Median cumulative doses of CDDP in TPF‑ICT and CRT were 180.0 and 206.7 mg/m², respectively. All patients completed 70 Gy RT. The complete response rate was 76.2%. At a median follow‑up of 51.5 months, median PFS and OS were not reached and 65.5 months, respectively. The most common grade 3 or worse toxicities during CRT‑ICT were stomatitis (48%), dysphagia (21%), anorexia (17%) and leukopenia (14%). However, no grade 2 or worse nephrotoxicity, neurotoxicity or ototoxicity was observed. The results demonstrated that concurrent CRT with split‑dose CDDP after TPF‑ICT is feasible and effective for LA‑SCCHN.

View Figures

View References

1	Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.PubMed/NCBI View Article : Google Scholar
2	Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE and Forastiere AA: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 21:92–98. 2003.PubMed/NCBI View Article : Google Scholar
3	Pignon JP, Bourhis J, Domenge C and Designé L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. MACH-NC collaborative group. Meta-analysis of chemotherapy on head and neck cancer. Lancet. 355:949–955. 2000.PubMed/NCBI
4	Pignon JP, le Maître A, Maillard E and Bourhis J: MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 92:4–14. 2009.PubMed/NCBI View Article : Google Scholar
5	Zhang L, Jiang N, Shi Y, Li S, Wang P and Zhao Y: Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: A meta-analysis. Sci Rep. 5(10798)2015.PubMed/NCBI View Article : Google Scholar
6	Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL and Vermorken JB: Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: Role, controversy, and future directions. Ann Oncol. 29:1130–1140. 2018.PubMed/NCBI View Article : Google Scholar
7	Budach W, Bölke E, Kammers K, Gerber PA, Orth K, Gripp S and Matuschek C: Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 118:238–243. 2016.PubMed/NCBI View Article : Google Scholar
8	Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, et al: Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol. 14:257–264. 2013.PubMed/NCBI View Article : Google Scholar
9	Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007.PubMed/NCBI View Article : Google Scholar
10	Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 357:1705–1715. 2007.PubMed/NCBI View Article : Google Scholar
11	Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, Bourredjem A, Calais G, Paccagnella A, Hitt R, et al: Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: An individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 31:2854–2860. 2013.PubMed/NCBI View Article : Google Scholar
12	Caballero M, Mackers P, Reig O, Buxo E, Navarrete P, Blanch JL and Grau JJ: The role of audiometry prior to high-dose cisplatin in patients with head and neck cancer. Oncology. 93:75–82. 2017.PubMed/NCBI View Article : Google Scholar
13	Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E and Noda Y: The risk factors of severe acute kidney injury induced by cisplatin. Oncology. 85:364–369. 2013.PubMed/NCBI View Article : Google Scholar
14	Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, et al: Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: Long-term report of efficacy and toxicity. J Clin Oncol. 32:3858–3866. 2014.PubMed/NCBI View Article : Google Scholar
15	Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK and Chan AT: Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 104:300–304. 2012.PubMed/NCBI View Article : Google Scholar
16	NCCN guidelines with NCCN evidence blocks^™-head and neck cancers version 1, 2020.
17	Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M, Tuchais C, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol. 31:853–859. 2013.PubMed/NCBI View Article : Google Scholar
18	Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, et al: A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol. 25:216–225. 2014.PubMed/NCBI View Article : Google Scholar
19	Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT and Urba SG: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer. A Southwest oncology group phase II trial (S0216). Head Neck. 32:221–228. 2010.PubMed/NCBI View Article : Google Scholar
20	Driessen CML, Leijendeckers J, Snik A, van der Graaf WTA, de Boer JP, Gelderblom H, Kaanders JHAM, Takes R and van Herpen CML: Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy. Head Neck. 41:488–494. 2019.PubMed/NCBI View Article : Google Scholar
21	Lieberthal W, Triaca V and Levine J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apoptosis vs. necrosis. Am J Phys. 270:F700–F708. 1996.PubMed/NCBI View Article : Google Scholar
22	Lee RH, Song JM, Park MY, Kang SK, Kim YK and Jung JS: Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells. Biochem Pharmacol. 62:1013–1023. 2001.PubMed/NCBI View Article : Google Scholar
23	Ozkok A and Edelstein CL: Pathophysiology of cisplatin-induced acute kidney injury. Biomed Res Int. 2014(967826)2014.PubMed/NCBI View Article : Google Scholar
24	Volarevic V, Djokovic B, Jankovic MG, Harrell CR, Fellabaum C, Djonov V and Arsenijevic N: Molecular mechanisms of cisplatin-induced nephrotoxicity: A balance on the knife edge between renoprotection and tumor toxicity. J Biomed Sci. 26(25)2019.PubMed/NCBI View Article : Google Scholar
25	Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M and Kiernan MC: Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 63:419–437. 2013.PubMed/NCBI View Article : Google Scholar
26	Oldenburg J, Fosså S and Dahl A: Scale for chemotherapy-induced long-term neurotoxicity (SCIN): Psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 15:791–800. 2006.PubMed/NCBI View Article : Google Scholar
27	LoMonaco M, Milone M, Batocchi AP, Padua L, Restuccia D and Tonali P: Cisplatin neuropathy: Clinical course and neurophysiological findings. J Neurol. 239:199–204. 1992.PubMed/NCBI View Article : Google Scholar
28	van den Bent MJ, van Putten WL, Hilkens PH, de Wit R and van der Burg ME: Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer. 38:387–391. 2002.PubMed/NCBI View Article : Google Scholar
29	von Schlippe M, Fowler CJ and Harland SJ: Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: Time course and prognosis. Br J Cancer. 85:823–826. 2001.PubMed/NCBI View Article : Google Scholar
30	Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR and Tredici G: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 69:203–207. 1992.PubMed/NCBI View Article : Google Scholar
31	Brydøy M, Oldenburg J, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Hauge ER, Dahl O and Fosså SD: Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 101:1682–1695. 2009.PubMed/NCBI View Article : Google Scholar
32	Okano S, Enokida T, Onoe T, Ota Y, Motegi A, Zenda S, Akimoto T and Tahara M: Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. Int J Clin Oncol. 24:789–797. 2019.PubMed/NCBI View Article : Google Scholar
33	Hitt R, Mesia R, Grau JJ, Iglesias L, Del Barco E, Lozano A, Trufero JM, Giron CG, Martin AL and Hernandez JJC: Randomized phase III trial of induction chemotherapy (ICT) with docetaxel-cisplatin-5fluorouracil (DCF) followed by cisplatin-radiotherapy (CRT) or cetuximab-radiotherapy (CetRT) in patients (pts) with locally advanced unresectable head and neck cancer (LAUHNC). J Clin Oncol. 34: (15 Suppl)(S6001)2016.